



**Online Controlled Substances Summit
Public Session**

Thursday, July 25, 2024
11 am to 2 pm (Eastern), Zoom Virtual Platform

Agenda

Moderator: *Susan C. Winckler, RPh, Esq.*

- 11 am** **Welcome**
Susan C. Winckler, RPh, Esq., Reagan-Udall Foundation for the FDA
- 11:05 am** **Introductory Remarks**
Robert M. Califf, MD, Commissioner of Food and Drugs, FDA
- 11:20 am** **Session 1: Perspectives from the FDA**
Presenters:
- *Leigh Verbois, PhD, Director, Office of Drug Security, Integrity, and Response, Office of Compliance, Center for Drug Evaluation and Research, FDA*
 - *Dan Burke, Chief, Investigative Services Division, Office of Criminal Investigations, FDA*
- 11:40 am** **Session 2: Perspectives from the Real World**
Presenters:
- *Coreen Johnson, Senior Project Coordinator, Young People in Recovery*
 - *Chris Wilks, PhD, MPA, Senior Consultant, Health Management Associates*
- 12 pm** **Session 3: Online Availability of Controlled Substances: A Snapshot**
Presenters:
- *Murray Aitken, MBA, MCom, Executive Director, IQVIA Institute for Human Data Science*
 - *Justin Macy, PharmD, JD, Chair of Alliance for Safe Online Pharmacies (ASOP) Global Foundation*
 - *Angie Hoth, PharmD, MPH, Research Consultant, Reagan-Udall Foundation for the FDA*
- Reactor Panelists:
- *Kaitlyn Brown, PharmD, DABAT, Clinical Managing Director, America's Poison Centers*

- *Sean Fearn, Chief, Community Outreach & Prevention Support, Office of Public Affairs, Drug Enforcement Administration*

1 pm **Session 4: Going Beyond the Message**

Presenters:

- *Tim Mackey, MAS, PhD, Professor, University of California, San Diego*
- *Erin Stack, MS, Director of Research and Evaluation, Comagine Health*

1:15 pm **Session 5: Perspectives from the Tech Sector**

Panelists:

- *Megan Jones Bell, PsyD, Clinical Director for Consumer and Mental Health, Google*
- *Amanda Plisner, JD, Senior Manager, Proactive Trust and Safety Operations, Snap Inc.*
- *Ernest Voyard, JD, Director, Public Policy, Meta*

1:55 pm **Closing Remarks**

Marta Sokolowska, PhD, Deputy Center Director, Substance Use and Behavioral Health, Center for Drug Evaluation and Research, FDA

2pm **Adjourn**